

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 61 (2005) 2295-2300

Total synthesis of four naturally occurring 2-azaanthraquinone antibiotics, 6-deoxy-8-methylbostrycoidin, 6-deoxybostrycoidin, 7-O-demethyl-6-deoxybostrycoidin and scorpinone

Tuyen Nguyen Van, Guido Verniest, Sven Claessens and Norbert De Kimpe*

Department of Organic Chemistry, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Gent, Belgium

Received 4 November 2004; revised 11 January 2005; accepted 12 January 2005

Available online 2 February 2005

Abstract—A total synthesis of four natural 2-azaanthraquinones, 6-deoxy-8-methylbostrycoidin, 6-deoxybostrycoidin, 7-O-demethyl-6-deoxybostrycoidin and scorpinone was accomplished using an optimized procedure for 2-azaanthraquinone synthesis, involving a [4+2]-cycloaddition protocol, of a polyoxygenated diene with a suitably functionalized benzoquinone, acetonylation with pyridinium ylids, cyclisation with ammonia and O-demethylation with boron(III) bromide. 2-Azaanthraquinones are rarely found in nature and reveal interesting physiological properties.

© 2005 Elsevier Ltd. All rights reserved.

1. Introduction

Naturally occurring 2-azaanthraquinones are of special interest due to their important physiological properties.¹ Benz[g]isoquinoline-5,10-dione **1**, the unsubstituted azaanthraquinone, has been isolated from *Psychotricha camponutans* and *Mitracarpus scaber*, and exhibits growth inhibition against multi-drug resistant pathogens, for example, *Staphylococcus aureus* and *Plasmodium falciparum*.^{1,2} This 2-azaanthraquinone **1** also revealed antimalarial activity, and recently, in vivo and in vitro trypanocidal activity against *Trypanosoma congolense* was discovered (Fig. 1).^{2,3}

Besides the unsubstituted 2-azaanthraquinone 1, also some oxygenated derivatives, for example, bostrycoidin 2 and analogues 3-8 as representative members, were found in nature and showed interesting activities. Bostrycoidin 2 and 9-*O*-methylbostrycoidin 3, two metabolites of numerous *Fusarium* species, showed antibiotic activity against the tubercle bacil and G⁺ bacteria, respectively.^{4,5} Tolypocladin 4, from the mycelium of *Tolypocladium inflatum*, displayed metal-chelating properties.⁶ In addition, 2-azaanthraquinone derivatives interfere with the activity of DNA topoisomerases and attract considerable attention in cancer chemotherapy as intercalating DNA binding agents.⁷ Recently, two new 2-azaanthraquinones, scorpinone 8 and

6-deoxy-8-methylbostrycoidin **5**, were identified in the mycelium of a Bispora-like tropical fungus and in the cultures of the mycobionts of the lichen *Haematomma* sp., respectively.^{8,9} From a yellow strain mutant of *Nectria haematococca*, grown in a medium enriched with asparagin 6-deoxybostrycoidin **6**¹⁰ and 7-*O*-demethyl-6-deoxybostry-coidin **7**¹¹ were isolated as intermediates in the bostrycoidin biosynthesis.

Because of the physiological importance of 2-azaanthraquinones, several methods have been developed for their synthesis. Most pathways deal with a Diels-Alder cyclization of appropriate building blocks, in which the nitrogen is already incorporated.^{12–14} However, these methods suffer from the disadvantage of low yield and poor regioselectivity of the incorporation of the methoxy groups. The synthetic pathway used by Watanabe et al. was based on a condensation of C(4)-lithiated nicotinamide with a 2,3,5trimethoxybenzamide as the key reaction for the construc-tion of the azaanthraquinones.¹⁴ The drawback of this regiospecific method is the low yield due to its multistep pathway, that is, condensation of aromatic rings, selective methylation at the pyridine ring, reduction, ring closure, oxidation and partial demethylation. Recently, we published a straightforward synthesis of 2-azaanthraquinones via an ammonia-induced cyclization of 2-acetonyl-3-bromo-methyl-1,4-naphthoquinones.¹⁵ An optimized procedure without the interference of side products, for example, naphtho[2,3-c]pyran-5,10-diones, was now developed to synthesize the natural product 6-deoxy-8-methylbostrycoidin 5 for the first time and to result in an improved

Keywords: 2-Azaanthraquinone; Natural products; Naphthoquinone.

^{*} Corresponding author. Tel.: +32 9 264 59 51; fax: +32 9 264 62 43; e-mail: norbert.dekimpe@UGent.be

^{0040–4020/\$ -} see front matter @ 2005 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2005.01.035

(tolypocladin)



1



2 $R^1 = R^4 = OH, R^2 = H, R^3 = OMe$ (bostrycoidin)

 $3 R^1 = R^3 = OMe, R^4 = OH$

4 $R^1 = R^3 = R^4 = OH, R^2 = H$



5 R^1 =OH, R^2 =Me, R^3 =OMe (6-deoxy-8-methylbostrycoidin) (9-O-methylbostrycoidin) **6** R^1 =OH, R^2 =H, R^3 =OMe (6-deoxybostrycoidin) **7** $R^1 = R^3 = OH, R^2 = H$ (7-O-demethyl-6-deoxybostrycoidin) **8** $R^1 = R^3 = OMe, R^2 = H$ (scorpinone)

Figure 1.

synthesis of three natural 2-azaanthraquinone antibiotics, 6-deoxybostrycoidin 6, 7-O-demethyl-6-deoxybostrycoidin 7 and scorpinone 8.

2. Results and discussion

The strategy for the synthetic pathway of the azaanthraquinones 5–8 consists of the synthesis of naphthoquinone 9 (LG, leaving group) which leads directly to the desired 2-azaanthraquinone system after treatment with ammonia via an intramolecular substitution (Scheme 1). The idea behind this approach was based on the hypothesis that naturally occurring 2-azaanthraquinones originate in vivo from the incorporation of ammonia into their O-analogues.¹⁶ The naphthoquinone skeleton can be synthesized by a cycloaddition of an appropriate electronrich and oxygenated diene 10 with the brominated benzoquinone 11. In this strategy the choice of the leaving group in naphthoquinone 9 is determining the outcome of the cyclization reaction towards 5-8. Earlier experiments showed that the use of a bromo atom as leaving group resulted in a mixture of pyranonaphthoquinones and 2-azaanthraquinones when treating naphthoquinones, analogous to 9, with ammonia. However, when phenoxide was used as a leaving group, the reaction gave predominantly rise to 2-azaanthraquinones with almost no side products.^{15,17}

For that reason 4,6-dibromo-2-(phenoxymethyl)phenol 14 was used as a starting material to synthesize 2-azaanthraquinones. The synthesis of 14 was accomplished by treating bromomethylphenol 13 with an excess of phenol under alkaline conditions. The latter brominated phenol 13 was synthesized by reacting o-cresol 12 with 3 equiv of bromine, first at 30 °C with 2 equiv of bromine to give the aromatic bromination, and afterwards at 120 °C with 1 equiv of bromine to introduce the bromine at the benzylic position.¹⁸ The substitution reaction of 13 with phenoxide was carried out in good yield without the need for protection of the hydroxyl function of the brominated cresol 13. Formation of byproducts was successfully suppressed by adding the brominated cresol to a refluxing solution of phenol in acetone in the presence of potassium carbonate (Scheme 2).

2,4-Dibromo-6-(phenoxymethyl)phenol 14 was oxidized by reaction with CrO₃ at room temperature to the benzoquinone 15, which served as a dienophile in the subsequent regioselective cycloaddition. (1,3-Dimethoxy-1,3-butadien-1-yloxy)trimethylsilane 10a was synthesized from methyl acetoacetate, while the analoguous 1,3-dimethoxy-2methyl-1,3-butadien-1-yloxy)trimethylsilane 10b was prepared from methyl 2-methylacetoacetate.¹⁹ These dienes 10a and 10b were subsequently reacted with benzoquinone 15 to yield the substituted naphthoquinones 16a-b in 62 and 55% yield, respectively. Dehydrobromination of the intermediate occurred spontaneously when treated with SiO₂ (during column chromatography). The naphthoquinones 16a-b, bearing a free hydroxyl function, were protected as methyl ethers 17a and 17b by reaction with iodomethane and silver(I) oxide, prior to the introduction of an acetonyl group.

In this way, 6,8-dimethoxy-2-(phenoxymethyl)-1,4naphthoquinones 17a-b were reacted with N-(acetylmethyl)pyridinium ylide, formed in situ by reaction of N-acetonylpyridinium chloride and triethylamine





Scheme 2.



(Scheme 3).²⁰ The acetonylated products **18a–b** were treated with 10 equiv of ammonia resulting in a nucleophilic addition across the carbonyl of the acetonyl moiety and intramolecular substitution of the phenoxy group. The cyclized product oxidized spontaneously and afforded 2-azaanthraquinone 19 in 72% yield (from 18a) and the natural product scorpinone 8 in 81% (from 18b). No naphtho[2,3-c]pyran-5,10-dione was formed as side product, contrary to reactions of similar substrates with a bromine instead of a phenoxy group as leaving group. To obtain the recently discovered natural product 6-deoxy-8methylbostrycoidin 5, compound 19 was 9-O-demethylated using boron(III) bromide in dichloromethane in 96% yield in the final step (Scheme 3). In order to obtain the natural product 6-deoxybostrycoidin 6, the natural product scorpinone 8 was selectively 9-O-demethylated by using 5 equiv of boron(III) bromide and stirring for 2 h at room temperature. A complete O-demethylation was obtained by reacting 8 with boron(III) tribromide in dichloromethane at room temperature for 48 h affording the natural product 7-O-demethyl-6-deoxybostrycoidin 7 in 86% yield.

In conclusion, using an optimized synthetic approach via dioxygenated 2-phenoxymethyl naphthoquinones, 2-azaanthraquinones were synthesized by cyclization of 2-phenoxymethyl-3-acetonylnaphthoquinones with ammonia. This reaction pathway resulted in the first straightforward synthesis of the natural product 6-deoxy-8-methylbostrycoidin **5** and an optimized procedure for the natural products scorpinone **8**, 6-deoxybostrycoidin **6** and 7-*O*-demethyl-6-deoxybostrycoidin **7**.

3. Experimental

3.1. General methods

¹H NMR spectra (270 MHz) and ¹³C NMR spectra (68 MHz) were run with a Jeol JNM-EX 270 NMR spectrometer. Peak assignments were performed with the aid of the DEPT technique, 2D-COSY spectra and HETCOR spectra. IR assignments were obtained from a Perkin Elmer Spectrum One spectrophotometer. Mass spectra were measured with an Agilent 1100 Series mass spectrometer (detector VL, 70 eV, ES 4000 V). Melting points were measured with a Buchi B-540 apparatus. The elemental analysis was performed on a Perkin Elmer 2400 Elemental Analyzer. Flash chromatography was carried out on a glass column with ACROS silica gel (particle size 0.035–0.07 mm, pore diameter ca. 6 nm). All solvents and reagents were obtained from commercial suppliers and were used without further purification.

3.1.1. 2,4-Dibromo-6-(phenoxymethyl)phenol (14). A solution of 2,4-dibromo-6-(bromomethyl)phenol 13^{15} (5 g, 14.5 mmol) in 50 ml of acetone was added dropwise to a refluxing mixture of phenol (13.6 g, 0.145 mol) and potassium carbonate (20 g, 0.145 mol) in 100 ml of acetone. After reflux overnight, the solvent was evaporated and the residue was redissolved in dichloromethane. After washing with water, the organic layer was dried over MgSO₄, filtered and evaporated in vacuo. Residual phenol was distilled off at high vacuum (0.5 mmHg, at 70 °C). To remove some minor

impurities, **14** was purified by column chromatography with 5% ethyl acetate in hexane as eluent, yielding 3.7 g of white crystals (71%), mp 68–69 °C. ¹H NMR (CDCl₃): δ 5.12 (2H, s, CH₂), 6.10 (1H, s, OH), 6.98–7.03 (3H, m, 3×=CH), 7.26–7.35 (2H, m, 2×=CH), 7.50 (1H, d, *J*=2.3 Hz, =CH), 7.58 (1H, d, *J*=2.3 Hz, =CH). ¹³C NMR (CDCl₃): δ 65.3 (CH₂O), 110.9 (C_{quat}), 112.7 (C_{quat}), 114.7 (2×=CH), 121.6 (=CH), 126.2 (C_{quat}), 129.6 (2×=CH), 130.6 (=CH), 133.5 (=CH), 149.2 (=C–O), 157.9 (=C–O). IR (KBr) ν 3408 (OH), 1598 (C=C), 1587 (C=C), 1497 (C=C), 1451 (C=C), 1245, 1222 cm⁻¹. MS *m/z* (%) 355/7/9 (M–H⁺, 100). Anal. Calcd C₁₃H₁₀Br₂O₂: C 43.61%, H 2.82%; found: C 43.24%, H 2.93%.

3.1.2. 2-Bromo-6-(phenoxymethyl)benzo-1,4-quinone (15). To a solution of 2,4-dibromo-6-(phenoxymethyl)phenol 14 (895 mg, 2.5 mmol) in 20 ml of HOAc:CH₃CN/ 4:1 was added CrO₃ (250 mg, 2.5 mmol) in 2 ml of aqueous HOAc (50%). The solution was stirred for 3 h at room temperature and, after completion of the oxidation, the mixture was poured in water and extracted with dichloromethane. Evaporation of the solvent in vacuo yielded 700 mg of crude benzoquinone 15, which was recrystallised from hexane:EtOAc/70:30 (600 mg, 82%), mp 145–146 °C. ¹H NMR (CDCl₃): δ 4.92 (1H, d, J = 2.0 Hz, CH_aH_bO), 4.96 $(1H, d, J=2.0 \text{ Hz}, CH_aH_bO), 6.94-7.05 (4H, m, 4 \times =CH),$ 7.26–7.35 (3H, m, $3 \times =$ CH). ¹³C NMR (CDCl₃): δ 63.5 (CH₂), 114.6 (2×=CH), 121.9 (=CH), 129.7 (2×=CH), 132.0 (=CH), 137.1, 138.2 and 144.0 (2×C_{quat}, 1×=CH), 157.4 (C_{quat}), 178.9 and 184.4 (2×C=O). IR (KBr) v 1674 (C=O), 1660 (C=O), 1634 (C=C), 1599 (C=C), 1498 (C=C), 1293, 1250 cm⁻¹. MS m/z (%) 293/5 (M-H⁺, 100). Anal. Calcd C₁₃H₇BrO₃: C 53.27%, H 3.09%; found: C 53.41%, H 3.21%.

3.1.3. 8-Hydroxy-6-methoxy-2-(phenoxymethyl)naphthoquinone (16a). To a solution of 2-bromo-6-(phenoxymethyl)benzo-1,4-quinone 15 (450 mg, 1.54 mmol) in 20 ml of dry toluene at -78 °C was added dropwise a solution of vinyl ketene acetal $10a^{17}$ (513 mg, 2.54 mmol) in 5 ml of toluene. The reaction was kept at this temperature for 30 min. Then, the resulting mixture was allowed to warm to room temperature and was stirred for 3 h. After the reaction mixture was filtered through silica gel, the filtrate was concentrated in vacuo and the resulting Diels-Alder adduct was recrystallized from ethanol to give 300 mg of the pure product **16a** (62%), mp 151–152 °C. ¹H NMR (CDCl₃): δ 3.90 (3H, s, CH₃O), 5.05 (2H, d, J= 2.3 Hz, CH₂), 6.64 (1H, d, J=2.3 Hz, H-5), 7.00 (1H, s, H-3), 7.03–7.07 (2H, m, 2×=CH), 7.08 (1H, t, J=2.3 Hz, C₃–H), 7.17 (1H, d, J=2.3 Hz, H-7), 7.21–7.36 (2H, m, 2× =CH), 12.10 (1H, s, OH). ¹³C NMR (CDCl₃): δ 53.1 (CH₃O), 63.2 (CH₂), 106.7 (C-7), 108.0 (C-5), 114.7 (2× =CH), 116.5 (C-9_{quat}), 121.7 (=CH), 129.7 (2×=CH), 132.6 (C-10_{quat}), 134.1 (C-3), 146.8 (C-2), 157.7 (=C-O), 164.5 (=C-O), 166.4 (=C-O), 183.8 and 187.6 ($2 \times$ C=O). IR (KBr) ν 1640 (C=O), 1620 (C=O), 1609 (C=C), 1588, 1388, 1311, 1241 cm⁻¹. MS *m*/*z* 497 (100), 311 (M+H⁺, 50). Anal Calcd $C_{18}H_{14}O_5$: C 69.67%, H 5.55%; found: C 69.55%, H 5.42%.

3.1.4. 8-Hydroxy-6-methoxy-7-methyl-2-(phenoxy-methyl)naphthoquinone (16b). Mp 188–189 °C (55%).

2299

¹H NMR (CDCl₃): δ 2.18 (3H, s, CH₃), 3.99 (3H, s, CH₃O), 5.07 (2H, d, J=2.0 Hz, CH₂O), 6.99–7.06 (3H, m, 3× =CH), 7.07 (1H, t, J=2 Hz, =CH), 7.21–7.36 (3H, m, 3× =CH), 12.21 (1H, s, OH). ¹³C NMR (CDCl₃): δ 8.1 (CH₃), 53.4 (CH₃O), 63.2 (CH₂), 102.5 (C-5), 109.7 (C_{quat}), 114.6 (2×=CH), 120.3 (C_{quat}), 121.7 (=CH), 129.0 (C_{quat}), 129.7 (2×=CH), 133.9 (C-3), 146.4 (C-2), 157.7 (=C–O), 161.3 (=C–O), 163.5 (=C–O), 184.2 and 188.2 (2× C=O). IR (KBr) ν 1661 (C=O), 1638 (C=O), 1609 (C=C), 1598 (C=C), 1497 (C=C), 1323, 1248, 1120 cm⁻¹. MS m/z (%) 323 (M–H⁺, 35), 309 (M–CH₃, 100).

3.1.5. 6,8-Dimethoxy-2-(phenoxymethyl)naphthoquinone (17a). To a solution of naphthoquinone 16a (256 mg, 0.83 mmol) in 10 ml of chloroform was added iodomethane (1.17 g, 8.3 mmol) and silver(I) oxide (2.02 g, 8.3 mmol). The mixture was refluxed for 3 h, under protection from light by covering the flask with aluminum foil. After cooling, the reaction mixture was filtered over celite and evaporated in vacuo to give 240 mg of the pure naphthoquinone 17a. The resulting product was pure and was used without further purification (90%), mp 176-177 °C. ¹H NMR (CDCl₃): δ 3.91 (3H, s, CH₃O), 3.94 (3H, s, CH₃O), 5.01 (2H, d, J=2.0 Hz, CH₂), 6.68 (1H, d, J=2.3 Hz, H-5), 6.94 (1H, s, H-3), 6.97–6.98 (2H, m, 2× =CH), 6.99 (1H, t, J=2.0 Hz, C₃-H), 7.19 (1H, d, J= 2.3 Hz, H-7), 7.26–7.32 (2H, m, $2 \times =$ CH). ¹³C NMR (CDCl₃): δ 56.3 and 56.7 (2×CH₃O), 64.2 (CH₂), 103.5 (CH-7), 104.4 (CH-5), 115.0 (2×=CH), 121.8 (=CH), 130.0 (2×=CH), 131.5 (C-3), 132.8 (C_{quat}), 136.3 (C_{quat}), 148.5 (C-2), 158.2, 162.4 and 165.2 (3×=C-O), 182.9 and 185.0 (2×C=O). IR (KBr) v 1651 (C=O), 1633 (C=O), 1597, 1458, 1331, 1251, 1159 cm⁻¹. MS m/z 325 (M+H⁺, 100). Anal. Calcd C₁₉H₁₆O₅: C 70.36%, H 4.79%; found: C 70.22%, H 5.18%.

3.1.6. 6,8-Dimethoxy-7-methyl-2-(phenoxymethyl)naphthoquinone (17b). Mp 151–153 °C (93%). ¹H NMR (CDCl₃): δ 2.23 (3H, s, CH₃), 3.85 (3H, s, CH₃O), 3.99 (3H, s, CH₃O), 5.07 (2H, d, J=2.0 Hz, CH₂), 6.98–7.06 (3H, m, 3×=CH), 7.07 (1H, t, J=2.0 Hz, C₃-H), 7.26–7.41 (3H, m, 3×=CH). ¹³C NMR (CDCl₃): δ 9.4 (CH₃), 56.5 and 61.4 (2×CH₃O), 64.2 (CH₂), 104.6 (CH-5), 115.0 (2× =CH), 118.6 (C_{quat}), 121.9 (=CH), 128.5 (C_{quat}), 130.0 (2×=CH), 132.0 (C-3), 133.2 (C_{quat}), 147.8 (C-2), 158.2, 160.4 and 163.1 (3×=C–O), 183.3 and 185.0 (2×C=O). IR (KBr) ν 1657 (C=O), 1634 (C=O), 1583, 1497, 1323, 1243, 1128 cm⁻¹. MS *m*/*z* (%) 339 (M+H⁺, 100). Anal. Calcd C₂₀H₁₈O₅: C 70.99%, H 5.36%; found: C 70.63%, H 5.54%.

3.1.7. 2-Acetonyl-5,8-dimethoxy-3-(phenoxymethyl)naphthoquinone (18a). To a solution of naphthoquinone 17a (220 mg, 0.68 mmol) and acetonylpyridinium chloride (174 mg, 1.02 mmol) in 10 ml acetonitrile was added dropwise a solution of triethylamine (82 mg, 1.02 mmol) in 2 ml of acetonitrile. The resulting mixture was stirred for 3 h at room temperature under a nitrogen atmosphere and protected from light. After evaporation of the solvent, 5 ml of aq 2 M HCl was added and extracted with ethyl acetate. The combined organic phases were washed with saturated NaHCO₃, dried (MgSO₄) and evaporated in vacuo. Purification by flash chromatography with 30% EtOAc in hexane as eluent yielded 200 mg of naphthoquinone 18a (83%), mp 146–147 °C. ¹H NMR (CDCl₃): δ 2.26 (3H, s, CH₃), 3.91 (3H, s, CH₃O), 3.92 (2H, s, CH₂C=O), 3.96 (3H, s, CH₃O), 5.08 (2H, s, CH₂O), 6.73 (1H, d, *J*=2.3 Hz, H-5), 6.90–6.98 (3H, m, 3×=CH), 7.22 (1H, d, *J*=2.3 Hz, H-7), 7.24–7.30 (2H, m, 2×=CH). ¹³C NMR (CDCl₃): δ 30.1 (CH₃C=O), 41.2 (CH₂C=O), 55.8 (CH₃O), 56.4 (CH₃O), 61.3 (CH₂O), 103.2 (C-7), 104.3 (CH-5), 114.2 (C_{quat}), 114.5 (2×=CH), 121.3 (=CH), 129.5 (2×=CH), 132.3 (C_{quat}), 135.5 (C-3), 141.4 (C-2), 158.0, 161.9 and 164.6 (3×=C–O), 181.4 and 184.6 (2×C=O), 203.3 (CH₃C=O). IR (KBr) ν 1715 (C=O), 1663 (C=O), 1654 (C=O), 1597, 1556, 1354, 1334, 1273, 1164 cm⁻¹. MS *m*/*z* 381 (M+H⁺, 100). Anal. Calcd C₂₂H₂₀O₆: C 69.46%, H 5.30%; found: C 69.52% H 5.42%.

3.1.8. 2-Acetonyl-5,7-dimethoxy-6-methyl-3-(phenoxymethyl)naphthoquinone (18b). Mp 162–163 °C (77%). ¹H NMR (CDCl₃): δ 2.22 (3H, s, CH₃), 2.29 (3H, s, CH₃), 3.83 (3H, s, CH₃O), 3.92 (2H, s, CH₂C=O), 3.96 (3H, s, CH₃O), 5.08 (2H, s, CH₂O), 6.91–7.00 (3H, m, 3×=CH), 7.25–7.31 (2H, m, 2×=CH), 7.38 (1H, s, C₅–H). ¹³C NMR (CDCl₃): δ 9.0 (CH₃), 30.2 (CH₃C=O), 41.2 (CH₂C=O), 56.1 (CH₃O), 61.0 and 61.2 (CH₂O and CH₃O), 104.3 (CH-5), 114.5 (2×=CH), 118.1 (C_{quat}), 121.4 (=CH), 128.5 (C_{quat}), 129.5 (2×=CH), 132.4 (C_{quat}), 142.0 (C_{quat}), 143.0 (C_{quat}) , 158.0, 159.6 and 162.5 $(3 \times = C-O)$, 181.8 and 184.6 (2×C=O), 203.5 (CH₃C=O). IR (KBr) ν 1696 (C=O), 1670 (C=O), 1626, 1580, 1334, 1222, 1143 cm⁻ MS m/z (%) (M+H⁺,100), 301 (M-C₆H₅O, 75). Anal. Calcd C₂₃H₂₂O₆: C 70.04%, H 5.62%; found: C 70.20%, H 5.48%.

3.1.9. 7,9-Dimethoxy-3-methylbenzo[*g*]isoquinoline-**5,10-dione (8, scorpinone).** To a solution of 3-acetonyl-5,7-dimethoxy-2-(phenoxymethyl)naphthoquinone **18a** (100 mg, 0.26 mmol) in 10 ml of ethanol was added dropwise a 25% aqueous solution of ammonia (0.43 ml, 5.2 mmol). The solution was protected from light and stirred at room temperature for 4 h in an open flask, allowing contact with air. After evaporation of the solvent, the residue was dissolved in CH₂Cl₂, washed with water, dried (MgSO₄) and evaporated. After recrystallization from ethanol 60 mg of 2-azaanthraquinone **8** was obtained (81%), mp 213–214 °C (lit. mp 195 °C).¹ Spectroscopic data (¹H NMR, ¹³C NMR, IR, MS) were in accordance with those reported in literature.^{1,8}

3.1.10. 7,9-Dimethoxy-3,8-dimethylbenzo[g]isoquinoline-5,10-dione (**19**). Mp 186–187 °C (72%). ¹H NMR (CDCl₃): δ 2.29 (3H, s, CH₃), 2.77 (3H, s, CH₃C=N), 3.93 (3H, s, CH₃O), 4.05 (3H, s, CH₃O), 7.60 (1H, s, =CH), 7.84 (1H, s, CH–C=N), 9.43 (1H, s, HC=N). ¹³C NMR (CDCl₃): δ 9.3 (CH₃), 25.1 (CH₃C=N), 56.2 and 61.3 (2×CH₃O), 104.7 (HC-5), 117.5 (HC–C=N), 119.5, 125.2, 130.0, 133.9 and 137.7 (5×C_{quat}), 149.6 (HC=N), 160.3, 162.9 and 164.4 (3×C_{quat}), 180.8 and 183.2 (2×C=O). IR (KBr) ν 1674 (C=O), 1661 (C=O), 1579, 1319, 1229, 1127 cm⁻¹. MS *m*/*z* (%) 298 (M+H⁺, 100). Anal. Calcd C₁₇H₁₅NO₄: C 68.68%, H 5.09%, N 4.71%; found: C 68.88%, H 4.96%, N 5.01%.

3.1.11. 6-Deoxy-8-methylbostrycoidin (6). To a solution of 2-azaanthraquinone **19** (120 mg, 0.4 mmol) in 10 ml of dry

dichloromethane was added dropwise boron(III) bromide (301 mg, 1.2 mmol) under a nitrogen atmosphere at -78 °C. After 30 min, the reaction was quenched with water and poured into 5 ml of 2 M NaOH. 1 M HCl was added in portions until the colour of the reaction mixture turned yellow. The resulting solution was extracted with dichloromethane, dried (MgSO₄) and evaporated. 6-Deoxy-8-methylbostrycoidin **6** was obtained as a pure product in almost quantitative yield (108 mg, 96%), mp 150–151 °C (decomposed, lit. mp⁹ 149–153 °C). Spectroscopic data (¹H NMR, ¹³C, IR, MS) were in accordance with those reported in literature.⁹

3.1.12. 7-Methoxy-9-hydroxy-3-methylbenzo[g]isoquinoline-5,10-dione (6-deoxybostrycoidin) (5). To a solution of 2-azaanthraquinone 8 (50 mg, 0.28 mmol) in 10 ml of dry dichloromethane was added dropwise boron(III) bromide (350 mg, 1.4 mmol) under a nitrogen atmosphere at -78 °C. After 30 min, the reaction was allowed to warm till room temperature. After stirring for 2 additional hours the reaction was quenched with water and poured into 5 ml 2 M NaOH. 1 M HCl was added in portions until the colour of the reaction mixture turned yellow. The resulting solution was extracted with dichloromethane, dried $(MgSO_4)$ and evaporated. 6-Deoxybostrycoidin 7 was obtained as a pure product in good yield (45 mg, 93%), mp 193–194 °C (lit. mp 195–196 °C). Spectroscopic data (¹H NMR, IR, MS) were in accordance with those reported in literature.¹⁰ ¹³C NMR (CDCl₃): δ 25.3 (CH₃), 56.1 (CH₃O), 107.4 (C-8), 108.2 (C-6), 110.4 (C_{quat}), 118.5 (C-4), 124.1 (C_{quat}), 134.5 (C_{quat}), 138.6 (C_{quat}), 149.1 (C-1), 165.5 (C-3), 165.9 (=C-O), 166.4 (=C-O), 182.2 (C=O), 186.1 (C=O).

3.1.13. 7,9-Dihydroxy-3-methylbenzo[g]isoquinoline-5,10-dione (7-O-demethyl-6-deoxy-bostrycoidin) (7). To a solution of 2-azaanthraquinone 8 (30 mg, 0.1 mmol) in 10 ml of dry dichloromethane was added dropwise boron(III) bromide (125 mg, 0.5 mmol) under a nitrogen atmosphere at -78 °C. The reaction mixture was kept at this temperature for 30 min, then the mixture was allowed to warm to room temperature and stirred for 48 h. After the reaction was quenched with water and poured into 5 ml 2 M NaOH, 1 M HCl was added in portions until the colour of the reaction mixture turned yellow. The resulting solution was extracted with dichloromethane, dried (MgSO₄) and evaporated to give the crude compound 7. This product was washed two times with dichloromethane and 7-O-demethyl-6-deoxybostrycoidin 7 was obtained as a pure product (22 mg, 86%), mp 291–292 °C (decomp.), lit.¹ mp 288– 290 °C (decomp.) lit.¹¹ mp 300–305 °C (decomp.). Spectroscopic data (¹H NMR, ¹³C NMR, IR, MS) were in accordance with those reported in literature.¹¹

Acknowledgements

The authors are indebted to the Janssen Research Foundation (Beerse, Belgium) and the IWT (Flemish Institute for the promotion of Scientific-Technological Research in Industry) for financial support.

References and notes

- 1. Krapcho, A. P.; Waterhouse, D. J. *Heterocycles* **1999**, *51*, 737–749.
- Okunade, A. L.; Clark, A. M.; Hufford, C. D.; Oguntimein, B. O. *Planta Med.* **1999**, 65, 447–448.
- Nok, A. J. Cell Biochem. Funct. 2002, 20, 205–212. Chem. Abstr. Nr. 2002, 636119.
- 4. Arsenault, G. P. Tetrahedron Lett. 1965, 45, 4033-4037.
- Steyn, P. S.; Wessels, P. L.; Marasas, W. O. F. *Tetrahedron* 1979, 35, 1551–1555.
- Gräfe, U.; Ihn, W.; Tresselt, D.; Miosga, N.; Kaden, U.; Schlegel, B.; Bormann, E.-J.; Sedmera, P.; Novak, J. *Biol. Metals* 1990, *3*, 39–44.
- 7. Khanapure, S. P.; Biehl, E. R. *Heterocycles* **1988**, *27*, 2643–2650.
- Miljkovic, A.; Mantle, P. G.; Williams, D. J.; Rassing, B. J. Nat. Prod. 2001, 64, 1251–1253.
- Moriyasu, Y.; Miyagawa, H.; Hamada, N.; Miyawaki, H.; Ueno, T. *Phytochemistry* 2001, 58, 239–241.
- Parisot, D.; Devys, M.; Barbier, M. Z. Naturforschung 1989, 44, 1473.
- 11. Parisot, D.; Devys, M.; Barbier, M. Z. *Phytochemistry* **1990**, 29, 3364–3365.
- Ohgaki, E.; Motoyoshima, J.; Narita, S.; Kakurai, T.; Hayashi, S.; Hirakawa, K.-I. J. Chem. Soc., Perkin Trans. 1 1990, 3109–3112.
- Cameron, D. W.; Deutscher, K. R.; Feutrill, G. I.; Hunt, D. E. Aust. J. Chem. 1982, 35, 1451–1468.
- Watanabe, M.; Shinoda, E.; Shimizy, Y.; Furukawa, S.; Iwao, M.; Kuraishi, T. *Tetrahedron* **1987**, *43*, 5281–5286.
- 15. Kesteleyn, B.; Nguyen Van, Y.; De Kimpe, N. *Tetrahedron* **1999**, *55*, 2091–2092.
- Parisot, D.; Devys, M.; Barbier, M. J. Antibiot. 1989, 42, 1189–1190.
- 17. Kesteleyn, B.; De Kimpe, N. J. Org. Chem. 2000, 65, 640-644.
- 18. Auwers, K.; Schröter, O. Annalen 1906, 344, 141-170.
- 19. Roush, W. R.; Coffey, D. S. J. Org. Chem. 1995, 60, 4412-4418.
- 20. (a) Aldersley, M. F.; Christi, S. H.; Dean, F. M.; Douglas, M. E.; Ennis, D. S. *J. Chem. Soc., Perkin Trans. 1* 1990, 2163–2174. (b) Aldersley, M. F.; Dean, F. M.; Hamzah, A. S. *Tetrahedron Lett.* 1986, 27, 255–258. (c) Kesteleyn, B.; Nguyen Van, T.; De Kimpe, N. *Tetrahedron* 1999, 55, 2091–2102. (d) Kesteleyn, B.; De Kimpe, N. *J. Org. Chem.* 2000, 65, 640–644.